Significantly improved upper gastrointestinal (UGI) tolerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I trial [abstract] - Goldstein, JL (European League Against Rheumatism)
Prague, Czech Republic, June 13–16, 2001.